Antimicrobial ReportsFirst Use of Investigational Antiviral Drug Pocapavir (V-073) for Treating Neonatal Enteroviral SepsisTorres-Torres, Sanet MD*; Myers, Angela L. MD, MPH*; Klatte, J. Michael MD*; Rhoden, Eric E.†; Oberste, M. Steven PhD†; Collett, Marc S.‡; McCulloh, Russell J. MD* Author Information From the *Pediatric Infectious Diseases, Children’s Mercy, Kansas City, MO; †Center for Disease Control and Prevention, Atlanta, GA; and ‡ViroDefense Inc., Rockville, MD. Accepted for publication June 30, 2014. The authors have no funding or conflicts of interest to disclose. Address for correspondence: Russell J. McCulloh, MD, Pediatric Infectious Diseases, Children’s Mercy Kansas City, 2401 Gillham Road, Kansas City, MO 64108. E-mail: [email protected]. The Pediatric Infectious Disease Journal: January 2015 - Volume 34 - Issue 1 - p 52-54 doi: 10.1097/INF.0000000000000497 Buy Metrics Abstract Neonatal enteroviral sepsis is a potentially fatal condition. Perinatally acquired infection and severe coagulopathy can be associated with a poor clinical outcome, and antiviral therapy is currently unavailable. Pocapavir (V-073) is an investigational drug candidate being developed for poliovirus indications, but also has variable antiviral activity against nonpolio enteroviruses. We describe the first use of pocapavir in treating a case of severe neonatal enteroviral sepsis due to Coxsackievirus B3. © 2015 by Lippincott Williams & Wilkins, Inc.